Keywords: |
immunohistochemistry; treatment outcome; middle aged; genetics; mutation; case report; patient selection; antineoplastic agents; chemotherapy, adjuvant; cancer staging; positron emission tomography; antineoplastic agent; neoplasm staging; gastrointestinal stromal tumor; imatinib; platelet derived growth factor alpha receptor; stem cell factor receptor; gastrointestinal stromal tumors; proto-oncogene proteins c-kit; receptor, platelet-derived growth factor alpha; computer assisted tomography; protein kinase inhibitor; tumor markers, biological; risk factors; tomography, x-ray computed; pathology; pyrimidines; tumor marker; risk factor; biopsy; protein kinase inhibitors; chemistry; adjuvant chemotherapy; positron-emission tomography; predictive value of tests; gastrectomy; piperazines; piperazine derivative; pyrimidine derivative; stomach neoplasms; b raf kinase; predictive value; proto-oncogene proteins b-raf; braf protein, human; stomach tumor; personalized medicine; benzamide derivative; benzamides; mitosis index; mitotic index; individualized medicine; multimodal imaging; humans; human; male; article
|